Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

Aim: Anti-CD20 monoclonal antibody is a cornerstone therapy for follicular lymphoma. Following anti-CD20 therapy, a potential decrease in CD20 antigen, and therefore a loss of the tumor target might be expected. However, the incidence and clinical significance of CD20 loss on tumor cells in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Michot, Jean-Marie, Buet-Elfassy, Alice, Annereau, Maxime, Lazarovici, Julien, Danu, Alina, Sarkozy, Clémentine, Chahine, Claude, Bigenwald, Camille, Bosq, Jacques, Rossignol, Julien, Romano-Martin, Patricia, Baldini, Capucine, Ghez, David, Dartigues, Peggy, Massard, Christophe, Ribrag, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094080/
https://www.ncbi.nlm.nih.gov/pubmed/35582306
http://dx.doi.org/10.20517/cdr.2020.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094080/
https://www.ncbi.nlm.nih.gov/pubmed/35582306
http://dx.doi.org/10.20517/cdr.2020.109

Ejemplares similares